Brokerages expect BRAINSWAY LTD/S (NASDAQ:BWAY) to announce ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BRAINSWAY LTD/S’s earnings, with estimates ranging from ($0.12) to ($0.10). The firm is scheduled to issue its next quarterly earnings results before the market opens on Monday, August 26th.
On average, analysts expect that BRAINSWAY LTD/S will report full-year earnings of ($0.43) per share for the current fiscal year, with EPS estimates ranging from ($0.48) to ($0.40). For the next year, analysts expect that the firm will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.38) to ($0.26). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its quarterly earnings data on Wednesday, May 29th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.00 million.
BWAY traded up $0.39 during trading hours on Friday, hitting $10.44. The stock had a trading volume of 30,586 shares, compared to its average volume of 13,330. The firm’s fifty day simple moving average is $9.93. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.33 and a current ratio of 1.33.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Noked Capital LTD purchased a new stake in BRAINSWAY LTD/S during the second quarter valued at $572,000. Victory Capital Management Inc. bought a new position in BRAINSWAY LTD/S during the second quarter valued at approximately $157,000. Delek Group Ltd. bought a new position in BRAINSWAY LTD/S during the second quarter valued at approximately $3,176,000. Finally, ARK Investment Management LLC bought a new position in BRAINSWAY LTD/S during the second quarter valued at approximately $863,000. Institutional investors and hedge funds own 3.64% of the company’s stock.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Further Reading: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.